This Article Full Text (PDF) All Versions of this Article: 0269881108089583v1 23/3/287    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barry, S Articles by Dinan, T. Search for Related Content PubMed PubMed Citation Articles by Barry, S Articles by Dinan, T. Social Bookmarking                         What's this?

Kynurenine pathway in psychosis: evidence of increased tryptophan degradation

Department of Psychiatry, The Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland sandra.barry{at}mailp.hse.ie

G Clarke

Department of Psychiatry, The Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland

P Scully

Department of Psychiatry, The Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland

TG Dinan

Department of Psychiatry, The Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland

Abstract

The kynurenine pathway of tryptophan degradation may serve to integrate disparate abnormalities heretofore identified in research aiming to elucidate the complex aetiopathogenesis of psychotic disorders. Post-mortem brain tissue studies have reported elevated kynurenine and kynurenic acid in the frontal cortex and upregulation of the first step of the pathway in the anterior cingulate cortex of individuals with schizophrenia. In this study, we examined kynurenine pathway activity by measuring tryptophan breakdown, a number of pathway metabolites and interferon gamma (IFN-), which is the preferential activator of the first-step enzyme, indoleamine dioxygenase (IDO), in the plasma of patients with major psychotic disorder. Plasma tryptophan, kynurenine pathway metabolites were measured using high-performance liquid chromatography (HPLC) in 34 patients with a diagnosis on the psychotic spectrum (schizophrenia or schizoaffective disorder) and in 36 healthy control subjects. IFN- was measured using enzyme-linked immunosorbent assay (ELISA). The mean tryptophan breakdown index (kynurenine/tryptophan) was significantly higher in the patient group compared with controls (P < 0.05). IFN- measures did not differ between groups (P = 0.23). No relationship was found between measures of psychopathology, symptom severity and activity in the first step in the pathway. A modest correlation was established between the tryptophan breakdown index and illness duration. These results provide evidence for kynurenine pathway upregulation, specifically involving the first enzymatic step, in patients with major psychotic disorder. Increased tryptophan degradation in psychoses may have potential consequences for the treatment of these disorders by informing the development of novel therapeutic compounds.

Key Words: tryptophan; kynurenine; psychosis

This version was published on May 1, 2009

Journal of Psychopharmacology, Vol. 23, No. 3, 287-294 (2009)
DOI: 10.1177/0269881108089583


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?